[ad_1]
The Commission today adopted a Pharmaceutical Strategy for Europe to ensure that patients have access to innovative and affordable medicines and to support the competitiveness, innovative capacity and sustainability of the EU pharmaceutical industry. The strategy will enable Europe to meet its pharmaceutical needs, even in times of crisis, through strong supply chains. A key component for building a stronger European Health Union, as requested by the President von der Leyen In his State of the Union address, the strategy will help establish a future-proof and crisis-resistant EU pharmaceutical system.
The European pharmaceutical strategy has four main objectives:
- Ensure access to affordable drugs for patients and address unmet medical needs (eg in the areas of antimicrobial resistance, cancer, rare diseases);
- Secondary competitiveness, innovation and sustainability of the EU pharmaceutical industry and the development of high-quality, safe, effective and greener medicines
- Getting better crisis preparedness and response mechanisms and address security of supply;
- Secure a strong voice of the EU in the world, promoting a high level of quality, efficacy and safety standards.
Although the Strategy is much more than a crisis response instrument, it draws lessons from the initial response to the COVID-19 pandemic and improves the European pharmaceutical sector. prepared and more resistant.
The Strategy presents concrete actions to ensure accessibility, availability and affordability of medicines. It supports diversified and secure supply chains, ensuring the open strategic autonomy of the EU in the world and promotes environmentally sustainable pharmaceutical products.
The Strategy will also ensure that EU pharmaceutical policy continues to serve public health in an ever-changing environment of scientific and commercial transformations. Will support patient-centered innovations and accommodate digital and technological change.
The members of the college said
President of the European Commission, Ursula von der Leyen, declared: “The coronavirus pandemic has highlighted the vital need to strengthen our health systems. This includes access to safe, effective and high-quality medicines at an affordable price. In challenging economic and social times the EU is going through, the strategy adopted today will ensure that Europe and Europeans continue to benefit from these medicines. I call on the Member States and Parliament to support this approach which will be implemented in the next three years and beyond.
Vice President of Promotion of the European lifestyle, Margaritis Schinas, said: “Safe and effective medications, vaccines and treatments have helped address some of the leading causes of life-threatening illnesses and diseases in the past. These products will be crucial in defending the health and well-being of European citizens in these difficult times. The current strategy helps the EU pharmaceutical industry to remain competitive and innovative, while addressing the needs of patients and our healthcare systems.. “
Stella Kyriakides, Commissioner of Health and Food Safety, highlighted: “Today we start work to ensure that safe and effective medicines are accessible and affordable at all times and for all patients in the EU. With our Pharmaceutical Strategy for Europe, we are delivering on our commitment to create a future-proof and patient-centered pharmaceutical environment in which the EU industry can innovate, prosper and remain a world leader. It is our long-term vision of open strategic autonomy, and our response to today’s challenges and vulnerabilities exposed by COVID-19. Today we are launching another pillar of the European Health Union ”.
Background
The Pharmaceutical Strategy for Europe marks the beginning of a process: its implementation includes a ambitious agenda of legislative and non-legislative actions to be released in the next few years.
The actions will cover the entire ecosystem of pharmaceutical products, but also some aspects of medical devices. Creates synergies with the Green Deal and our actions under the EU’s strategic focus on pharmaceuticals in the environment to reduce their environmental risk, address pharmaceutical waste contamination and promote greener manufacturing, use and disposal (there is a report from progress available). It is also linked to the action plan on Intellectual Property presented today.
the badge actions of the Strategy include:
- A review of basic pharmaceutical legislation * (deadline for a proposal: 2022) in order to make this framework future-proof and compatible with innovation;
- A proposal for an EU Health Emergency Response Authority (proposal: 2North Dakota semester 2021);
- A review of the regulations on medicines for children and rare diseases
- Initiate a structured dialogue with and between all pharmaceutical manufacturing actors and public authorities to identify vulnerabilities in the global supply chain of critical medicines and shape policy options to strengthen continuity and security of supply in the EU;
- Cooperation between national authorities on pricing, payment and procurement policies, to improve the affordability, profitability of medicines, and the sustainability of the health system;
- The creation of a robust digital infrastructure, including a proposal for a European health data space (deadline for a proposal: 2021);
- Support for research and innovation, in particular through Horizon 2020 and EU4Health;
- Actions to promote innovative approaches to EU R&D and public procurement of antimicrobials and their alternatives and measures to restrict and optimize their use.
Related
[ad_2]
